一图解码：森亿智能递表港交所 AI医疗独角兽 亏损收窄

Core Viewpoint - Senyi Intelligent has submitted its prospectus to the Hong Kong Stock Exchange, planning to list on the main board, positioning itself as a leading AI medical technology company with comprehensive solutions from L1 to L4 levels in the global AI medical industry [3][4]. Group 1: Company Overview - Senyi Intelligent is recognized as the only company in the global AI medical sector that offers solutions covering L1 to L4 levels, showcasing its full-stack technology development capabilities from data infrastructure to application layer algorithms and software [7][8]. - The company has been deeply engaged in the Chinese healthcare sector for many years, primarily serving hospitals and medical groups, maintaining a leading position in this niche market [8]. Group 2: Market Position - According to a report by Zhaoshang Consulting, Senyi Intelligent is the largest hospital AI medical solution provider in China based on hospital revenue projections for 2024, and it ranks as the fourth largest provider globally [9][10]. - As of June 30, 2025, Senyi Intelligent has served over 750 hospitals, including more than 400 large hospitals [10]. Group 3: Financial Performance - For the six months ending June 30, 2025, Senyi Intelligent reported revenue of approximately 112 million RMB, representing a year-on-year growth of about 23.3%. The net loss attributable to the parent company was approximately 91.87 million RMB, narrowing by about 5.7% year-on-year [3][12][13]. Group 4: Fundraising Purpose - The net proceeds from the IPO are intended for enhancing research and innovation capabilities, improving existing products and solutions, boosting commercialization efforts and establishing a global channel network, acquiring synergistic companies such as medical device manufacturers, and for working capital and other general corporate purposes [4][5]. Group 5: Technological Capabilities - Senyi Intelligent's solutions have executed over 23 million assessments monthly on average, supporting disease risk assessments for approximately 37 million patients and establishing over 1,600 specialized disease databases and research projects [11].